FOLH1 and prostate carcinoma: NCT05146973 aims to assess the effectiveness of 177Lu-TLX591, a radiolabelled PSMA-targeting antibody, in combination with external beam radiation therapy (EBRT) for the treatment of biochemically recurrent, oligometastatic, PSMA-expressing prostate cancer.